In addition to Florida, the Texas-Mexico border could become a hotbed of chikungunya transmission, said Scott Weaver, director of the Institute for Human Infections and Immunity and scientific director of the Galveston National Laboratory at UTMB. Several chikungunya vaccines are under development. Weaver's group is partnered with Takeda Pharma and is working on a live attenuated vaccine that has shown promise in nonhuman primates, he said. Another vaccine recently went into human trials in Europe and uses a measles virus vector. Still another, a non–live replicating vaccine developed by the National Institutes of Health, was "fairly immunogenic" in phase 1 human clinical trials.